Why VeriStrat®
Epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) are an effective, targeted therapy for advanced non-small cell lung cancer (NSCLC), but not all patients benefit from treatment.1 Identifying appropriate patients for therapy is key to improving patient outcomes. Several molecular tests and clinical factors are currently utilized to help identify patients who may derive benefit from EGFR-TKI therapy.2
VeriStrat is a unique, proteomic test that uses matrix assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry (MS) to reliably characterize protein content in pretreatment serum samples. VeriStrat is intended to be used for patients with advanced NSCLC who have progressed after first line therapy. VeriStrat identifies patients who are likely to have good or poor outcomes following treatment with EGFR-TKI therapy. VeriStrat results are independent of patient characteristics, such as histology, gender, ethnicity and smoking history.3
When determining the selection of either single agent chemotherapy or EGFR-TKI therapy for patients with advanced NSCLC, VeriStrat provides additional information to help guide clinical judgment. VeriStrat test results are typically provided within 72 hours of sample shipment.
References
1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
2. Herbst RS, Sandler A. Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC. The Oncologist. 2008;13:1166-1176.
3. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007;99:838-846.